Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech acquired 50,000 shares of Radius Health stock in a transaction that occurred on Tuesday, September 5th. The shares were bought at an average cost of $36.75 per share, with a total value of $1,837,500.00. Following the transaction, the insider now owns 5,298,799 shares in the company, valued at $194,730,863.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Shares of Radius Health, Inc. (NASDAQ RDUS) opened at 36.60 on Friday. Radius Health, Inc. has a one year low of $31.58 and a one year high of $59.22. The company’s market cap is $1.59 billion. The company has a 50 day moving average price of $38.51 and a 200 day moving average price of $39.43.

Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by $0.23. The company had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.96 million. During the same quarter last year, the firm posted ($1.01) earnings per share. Equities analysts predict that Radius Health, Inc. will post ($5.58) EPS for the current year.

WARNING: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/09/growth-n-v-biotech-buys-50000-shares-of-radius-health-inc-rdus-stock.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DUPONT CAPITAL MANAGEMENT Corp acquired a new position in shares of Radius Health in the 1st quarter valued at $304,000. OppenheimerFunds Inc. increased its position in shares of Radius Health by 0.3% in the 1st quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock valued at $11,658,000 after acquiring an additional 831 shares during the period. American International Group Inc. increased its position in shares of Radius Health by 7.1% in the 1st quarter. American International Group Inc. now owns 19,430 shares of the biopharmaceutical company’s stock valued at $751,000 after acquiring an additional 1,284 shares during the period. Trexquant Investment LP acquired a new position in shares of Radius Health in the 1st quarter valued at $241,000. Finally, BlackRock Inc. increased its position in shares of Radius Health by 98,245.6% in the 1st quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after acquiring an additional 2,628,070 shares during the period.

A number of research analysts recently weighed in on RDUS shares. Jefferies Group LLC set a $34.00 price objective on Radius Health and gave the company a “hold” rating in a research report on Monday, June 5th. ValuEngine raised Radius Health from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. BidaskClub raised Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Cantor Fitzgerald set a $65.00 target price on Radius Health and gave the stock a “buy” rating in a report on Monday, May 22nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $53.60.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.